Abolfazl Avan

Dr. Abolfazl Avan

Mashhad University of Medical Sciences, Mashhad, Khorāsān-e Raẕavī, Iran
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2015 in The Oncologist
Verified
Journal Article
Closed access
PDF file
AAAbolfazl Avan
Abolfazl Avan
TPTjeerd J. Postma
Tjeerd J. Postma
CCCecilia Ceresa
Cecilia Ceresa
AAAmir Avan
Amir Avan
Guido CavalettiGuido Cavaletti
Guido Cavaletti
Godefridus J. PetersGodefridus J. Peters
Godefridus J. Peters
Neurotoxicity is a burdensome side effect of platinum-based chemotherapy that prevents administration of the full efficacious dosage and often leads to treatment withdrawal. Peripheral sensory neurotoxicity varies from paresthesia in fingers to ataxic gait, which might be transient or irreversible. Because the number of patients being treated with these neurotoxic agents is still increasing, the need for understanding the pathogenesis of this dramatic side effect is critical. Platinum derivatives, such as cisplatin and carboplatin, harm mainly peripheral nerves and dorsal root ganglia neurons, possibly because of progressive DNA-adduct accumulation and inhibition of DNA repair pathways (e.g., extracellular signal-regulated kinase 1/2, c-Jun N-terminal kinase/stress-activated protein kinase, and p38 mitogen-activated protein kinass), which finally mediate apoptosis. Oxaliplatin, with a completely different pharmacokinetic profile, may also alter calcium-sensitive voltage-gated sodium channel kinetics through a calcium ion immobilization by oxalate residue as a calcium chelator and cause acute neurotoxicity. Polymorphisms in several genes, such as voltage-gated sodium channel genes or genes affecting the activity of pivotal metal transporters (e.g., organic cation transporters, organic cation/carnitine transporters, and some metal transporters, such as the copper transporters, and multidrug resistance-associated proteins), can also influence drug neurotoxicity and treatment response. However, most pharmacogenetics studies need to be elucidated by robust evidence. There are supportive reports about the effectiveness of several neuroprotective agents (e.g., vitamin E, glutathione, amifostine, xaliproden, and venlafaxine), but dose adjustment and/or drug withdrawal seem to be the most frequently used methods in the management of platinum-induced peripheral neurotoxicity. To develop alternative options in the treatment of platinum-induced neuropathy, studies on in vitro models and appropriate trials planning should be integrated into the future design of neuroprotective strategies to find the best patient-oriented solution.

31 May 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
AAAbolfazl Avan
Abolfazl Avan
VHVladimir Hachinski
Vladimir Hachinski

22 March 2021 in The Neuroradiology Journal
Verified
Journal Article
Open access
PDF file
NMNaghmeh Mokhber
Naghmeh Mokhber
ASAidin Shariatzadeh
Aidin Shariatzadeh
AAAbolfazl Avan
Abolfazl Avan
HSHamidreza Saber
Hamidreza Saber
GBGolnaz Shojaeian Babaei
Golnaz Shojaeian Babaei
MAMahmoud Reza Azarpazhooh
Mahmoud Reza Azarpazhooh
We aimed to summarize the available evidence on cerebral blood flow (CBF) changes in normal aging and common cognitive disorders. We searched PubMed for studies on CBF changes in normal aging and cognitive disorders up to 1 January 2019. We summarized the milestones in the history of CBF assessment and reviewed the current evidence on the association between CBF and cognitive changes in normal aging, vascular cognitive impairment (VCI) and Alzheimer’s disease (AD). There is promising evidence regarding the utility of CBF studies in cognition research. Age-related CBF changes could be related to a progressive neuronal loss or diminished activity and synaptic density of neurons in the brain. While a similar cause or outcome theory applies to VCI and AD, it is possible that CBF reduction might precede cognitive decline. Despite the diversity of CBF research findings, its measurement could help early detection of cognitive disorders and also understanding their underlying etiology.

27 September 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
AAAbolfazl Avan
Abolfazl Avan
VHVladimir Hachinski
Vladimir Hachinski
TGthe Brain Health Learn and Act Group
the Brain Health Learn and Act Group

Verified
Journal Article
Open access
PDF file
AAAbolfazl Avan
Abolfazl Avan
ACAnna Czlonkowska
Anna Czlonkowska
SGSusan Gaskin
Susan Gaskin
AGAlberto Granzotto
Alberto Granzotto
SSStefano L. Sensi
Stefano L. Sensi
DWDing Weilun
Ding Weilun
Wilson’s disease (WD) is a hereditary disorder of copper metabolism, producing abnormally high levels of non-ceruloplasmin-bound copper, the determinant of the pathogenic process causing brain and hepatic damage and dysfunction. Although the disease is invariably fatal without medication, it is treatable and many of its adverse effects are reversible. Diagnosis is difficult due to the large range and severity of symptoms. A high index of suspicion is required as patients may have only a few of the many possible biomarkers. The genetic prevalence of ATP7B variants indicates higher rates in the population than are currently diagnosed. Treatments have evolved from chelators that reduce stored copper to zinc, which reduces the toxic levels of circulating non-ceruloplasmin-bound copper. Zinc induces intestinal metallothionein, which blocks copper absorption and increases excretion in the stools, resulting in an improvement in symptoms. Two meta-analyses and several large retrospective studies indicate that zinc is equally effective as chelators for the treatment of WD, with the advantages of a very low level of toxicity and only the minor side effect of gastric disturbance. Zinc is recommended as a first-line treatment for neurological presentations and is gaining acceptance for hepatic presentations. It is universally recommended for lifelong maintenance therapy and for presymptomatic WD.

9 August 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
Rosanna SquittiRosanna Squitti
Rosanna Squitti
Amit PalAmit Pal
Amit Pal
MPMario Picozza
Mario Picozza
AAAbolfazl Avan
Abolfazl Avan
MVMariacarla Ventriglia
Mariacarla Ventriglia
THTjaard Hoogenraad
Tjaard Hoogenraad
Zinc therapy is normally utilized for treatment of Wilson disease (WD), an inherited condition that is characterized by increased levels of non-ceruloplasmin bound (‘free’) copper in serum and urine. A subset of patients with Alzheimer’s disease (AD) or its prodromal form, known as Mild Cognitive Impairment (MCI), fail to maintain a normal copper metabolic balance and exhibit higher than normal values of non-ceruloplasmin copper. Zinc’s action mechanism involves the induction of intestinal cell metallothionein, which blocks copper absorption from the intestinal tract, thus restoring physiological levels of non-ceruloplasmin copper in the body. On this basis, it is employed in WD. Zinc therapy has shown potential beneficial effects in preliminary AD clinical trials, even though the studies have missed their primary endpoints, since they have study design and other important weaknesses. Nevertheless, in the studied AD patients, zinc effectively decreased non-ceruloplasmin copper levels and showed potential for improved cognitive performances with no major side effects. This review discusses zinc therapy safety and the potential therapeutic effects that might be expected on a subset of individuals showing both cognitive complaints and signs of copper imbalance.